Precision for Medicine Acquires ACT Oncology         


Chief Financial Officer

Gene Vodovoz serves as the Chief Financial Officer for ACT Oncology. Gene is responsible for leading the finance organization and supporting strategic planning and business operations.  As a member of the Executive Team, Gene also supports the planning and execution of enhancements to ACT Oncology’s framework and infrastructure, to support company growth.

Gene has over 20 years of professional experience and has held key financial and general management positions in the drug development services industry. Most recently, he was Vice President of Finance and Chief Accounting Officer at a large CRO where he enhanced company profitability and improved operational efficiencies across the finance division. Gene has held several financial management positions at The McGraw-Hill Companies, Inc., Agere Systems, Inc., Honeywell International, Inc., and Deloitte and Touché, LLP.

Gene received a Bachelor of Science degree in Accounting from Rutgers University and is a Certified Public Accountant in the State of New Jersey. He is also certified as a Six Sigma Green Belt.

Gene VodovozLowRes_0076_013

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at to see how we’re delivering the next generation of CRO services for oncology innovators.